Krystal Biotech, Inc. (KRYS) Net Margin
- 2026-06-30: Net Margin 45.94%.
- 2026-03-31: Net Margin 48.07%.
- 2025-12-31: Net Margin 47.99%.
- 2025-09-30: Net Margin 81.15%.
Complete source-backed net margin history.
- Available history
- 2023-09-30 to 2026-06-30
- Data captured
Historical Net Margin
| Date | Net Margin |
|---|---|
| 2026-06-30 | 45.94% |
| 2026-03-31 | 48.07% |
| 2025-12-31 | 47.99% |
| 2025-09-30 | 81.15% |
| 2025-06-30 | 39.91% |
| 2025-03-31 | 40.52% |
| 2024-12-31 | 49.90% |
| 2024-09-30 | 32.42% |
| 2024-06-30 | 22.15% |
| 2024-03-31 | 2.06% |
| 2023-12-31 | 20.63% |
| 2023-09-30 | 943.75% |
Annual Net Margin
| Date | Net Margin |
|---|---|
| 2025-12-31 | 52.64% |
| 2024-12-31 | 30.69% |
| 2023-12-31 | 21.56% |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |